Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab in BCG-failed or BCG-intolerant non-muscle invasive bladder cancer
CTR20210616Phase 2Active
- Sponsor
- Linton Pacific
- Start
- Nov 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of catumaxomab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Linton Pacific. Started Nov 2021; status: active.
02
Drugs
catumaxomab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20210616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210616.